Also found in: Dictionary, Thesaurus, Medical.



medicinal substances that suppress the activity of the clotting system of the blood and obstruct the formation of thrombi.

Anticoagulants affect various links in the process of blood clotting. One may distinguish anticoagulants with direct effect (heparin, hirudin, etc.), which lower the activity of thrombin in the blood; and anticoagulants with indirect effect (dicoumarin, “neodikumarin,” or Pelentan, phenin-dione, “sinkumar,” etc.), which disrupt the formation in the liver of prothrombin, which participates in blood coagulation. Certain preparations that are not classed as anticoagulants also decrease the coagulability of the blood, such as sodium citrate, sodium salicylate, and acetylsalicylic acid. (These bind the calcium in blood, which plays a part in blood clotting.) Anticoagulants are used in myocardial and pulmonary infarctions, in thrombotic and embolic insults, in cases of thrombophlebitis, and in other cases; they are used prophylactically in atherosclerosis of the coronary arteries and the cerebral blood vessels and in rheumatic mitral defects of the heart; in surgery they are used to prevent formation of thrombi in the postoperative period. Anticoagulants are contraindicated in cases of ulcers, kidney stones, diseases that incline to hemorrhage, and pregnancy.


Zakusov, V. V. Farmakologiia, 2nd ed. Moscow, 1966.


References in periodicals archive ?
Like heparin, the newly isolated tick anticoagulant peptide (TAP) interrupts the chain of enzyme reactions that produces fibrin, an insoluble mesh of protein that gives structure to a blood clot.
They are also likely to grab substantial market share from the parenteral anticoagulants for prophylaxis of venous thromboembolism in orthopedic joint replacement surgery.
The leading anticoagulants will be Bristol-Myers Squibb/Pfizer's Eliquis, Daiichi Sankyo's Lixiana and Boehringer Ingelheim's Pradaxa.
EP217609 has Potential to Replace Heparin as the Reversible Anticoagulant of Choice
According to IPRO pharmacist and tool developer Anne Myrka, "the failure to effectively communicate critical elements such as when the next dose of an anticoagulant is due or when it should be discontinued can result in significant patient harm, and even death.
Other key findings from the Emerging Markets Physician and Payer Forum report entitled Novel Oral Anticoagulants in LATAM (Brazil and Mexico): Physician and Payer Perspectives on the Evolving Treatment of Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome include:
Industry Overview II-3 The Pharmaceuticals Industry II-3 Industry Framework II-3 Regulatory Price Controls - Present and Future II-3 Consolidations Driving the Industry II-4 Patent Expiries Giving Way to Generic Drugs II-4 Anticoagulants Sector II-4 A Snapshot of Available Therapies II-4 An Insight into Currently Available Antithrombotic Drugs II-5 Weaknesses of Available Therapies II-5 Forces Driving the Market II-6 Oral Anticoagulants Market II-6 Injectable Anticoagulants Market II-6 Heparin Market II-6 LMWH Market II-7
The Medicines and Healthcare products Regulatory Agency (MHRA) has launched an online learning module for healthcare professionals on reducing the side effects of oral anticoagulants.
In community-based, real-world practice, use of novel anticoagulants in the older population was substantial and increasing," and the results were also "reassuring" about the efficacy and safety of these drugs during routine use, particularly in the elderly, said Dr.
For more than 50 years and until recently, the only oral anticoagulants were vitamin K antagonists such as warfarin.
Washington, Oct 26 (ANI): A new study has suggested that men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half.

Full browser ?